U.S., Aug. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07120633) titled 'Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL' on July 25.
Brief Summary: At present, there is a lack of relevant research on the first-line treatment of high-risk CLL patients with BTKi combined with CAR-T. Therefore, our center plans to conduct a study on the treatment of newly diagnosed high-risk CLL patients with AntiCD19 CAR-T combined with BTKi, in order to increase the uMRD rate of newly diagnosed high-risk patients, thereby improving the long-term prognosis of high-risk CLL patients and reducing the long-term medication rate of CLL patients, providing more treatment options and hope for newly ...